Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-30
2005-08-30
Jones, Dwayne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263100, C514S263200
Reexamination Certificate
active
06936618
ABSTRACT:
The use of a type V cyclic nucleotide phosphodiesterase inhibitor for the preparation of a medicament for the treatment of cystic fibrosis.
REFERENCES:
patent: 5602110 (1997-02-01), Drumm et al.
patent: 5728705 (1998-03-01), Lawson et al.
McPherson et al. “A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein,” FEBS LETT. vol. 464, pp. 48-52, 1999.
Dormer Robert Leslie
McPherson Margaret Ann
Jones Dwayne C.
University of Wales College of Medicine
Young & Thompson
LandOfFree
Cystic fibrosis medicaments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cystic fibrosis medicaments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cystic fibrosis medicaments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3481863